ASM/ESCMID

Novavax VP Matthew Rousculp on reactogenicity, vaccine Hesitancy, and supporting informed decisions.

At ESCMID 2025, SHIELD study data show Novavax recipients experienced fewer side effects and missed less work compared to those who received the Pfizer-BioNTech COVID-19 vaccine.

Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.

Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of
Clinical Microbiology and Infectious Diseases.

The PERSEUS study aimed to assess the effectiveness and safety of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin presented at the 34th ESCMID Global conference.